{"entity":{"id":"idea-fund-sovereign-first-in-class-coinvestment","kind":"idea","name":"Public co-investment in first-in-class phase 1 with a royalty return","aka":[],"tldr":"A public investment fund would match private money in the riskiest early trials of truly new cancer drugs, taking a small share of future royalties so that taxpayers gain when the bets pay off.","summary":"A sovereign or supranational fund co-invests one-to-one alongside private investors in phase 1 trials of assets that meet a first-in-class test (a target or mechanism with no approved analogue), in exchange for a royalty stake or equity. The fund's return is portfolio-level and long-term; its purpose is to lower the private cost of capital for novel mechanisms relative to me-too assets. The Cancer Prevention and Research Institute of Texas (CPRIT) and the California Institute for Regenerative Medicine (CIRM) show public bodies can invest in translational biotech with revenue-sharing and attract companies; the EU's Innovative Health Initiative and BARDA venture arms are related models.","asOf":"2026-09-08","links":[{"label":"CPRIT","url":"https://www.cprit.texas.gov/"},{"label":"CIRM","url":"https://www.cirm.ca.gov/"}],"tags":[],"related":["idea-fund-ind-enabling-fund","idea-fund-royalty-pool-academic-assets","idea-fund-phase-two-failure-reinsurance"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cprit"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-incentive-misalignment","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Public co-investment reduces the first-in-class discount in private financing (the gap in valuation and time to raise between novel and follow-on assets) measurably within five years and yields a portfolio return that covers the fund's costs within fifteen.","rationale":"CPRIT has committed billions with a documented multiplier in private follow-on investment and company relocation; CIRM funded therapies now in late-stage trials. Public capital is patient and can accept the higher failure rate of novelty in exchange for a share of rare large wins.","test":"Capitalise a fund at $500 million, invest only in assets passing an independent first-in-class test, and compare private follow-on financing and time-to-phase-2 of funded assets against matched unfunded novel assets after five years.","maturity":"speculative","actor":"policy","cost":"large","horizonYears":6},"route":"/ideas/idea-fund-sovereign-first-in-class-coinvestment/","neighbours":{"idea":[{"id":"idea-fund-royalty-pool-academic-assets","kind":"idea","name":"A diversified royalty pool that finances academic phase 1 trials across fifty assets","route":"/ideas/idea-fund-royalty-pool-academic-assets/"},{"id":"idea-fund-ind-enabling-fund","kind":"idea","name":"A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks","route":"/ideas/idea-fund-ind-enabling-fund/"},{"id":"idea-fund-phase-two-failure-reinsurance","kind":"idea","name":"Government reinsurance for phase 2 failures of first-in-class cancer drugs","route":"/ideas/idea-fund-phase-two-failure-reinsurance/"}],"institution":[{"id":"cprit","kind":"institution","name":"Cancer Prevention and Research Institute of Texas","route":"/institutions/cprit/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}]}}